Despite having a relatively low transfer factor (TF), A
After the shortage ended and enforcement discretion lapsed in early 2025, compounded tirzepatide is allowed through a 503A pharmacy only for a documented individualized clinical need an approved product cannot meet
It is currently a very exciting time within drug development for incretins, but there is still a lot we dont know
Rather than partnering with Novo on semaglutide, which is now copyable, Cipla partnered with Eli Lilly on tirzepatide, launching Yurpeak in India in late 2025
Estrogen alone may not fully overcome insulin resistance in the setting of obesity, while GLP-1 therapies do not directly restore the hormonal environment that supports mitochondrial and tissue-level function
GLP-1 Weight management medications GLP-1 weight loss Which GLP-1 works best for weight loss